Stem cell therapy may stop and reverse MS, but risks remain

Scientists building on earlier research into stem cells have managed to halt multiple sclerosis (MS) in a clinical trial, but the treatment is not suitable for patients with an advanced stage of the disease.

In 10 seconds? A large trial involving MS patients found that stem cell therapy was stopping relapses and disease progress in almost all participants — the best result yet in any MS-related trial — and the benefits lasted up to 3 years. (See the science)

What happened? Researchers tested whether wiping out a patient’s immune system and rebuilding it with stem cells could stop and reverse MS — which is what happened for most of the patients in the treatment group. Of the 52 study participants given the ‘stem cell reboot’, only one of them relapsed a year later. (Read the preliminary results here)

How did they do it? Knowing that MS damages nerves due to an undesired overreaction in the patients’ immune system, scientists used chemotherapy to firstly wipe out their immune system. They then injected blood-cell-generating stem cells harvested from the patients’ own bone marrow by drip-feed into the bloodstream, achieving a ‘clean re-install’ of their immune system. (More on how it’s done)

So, the problem went away? Seems so! One year after the treatment almost everyone was symptom-free. Three years later still, 94% of the group was still relapse-free. To compare, in the control group, 60% of people suffered an MS relapse in same period. (More on cell-based MS treatments)

And how did the patients feel? The trial — and similar treatments elsewhere — were cathartic for many. One patient described receiving the stem cells as a ‘rebirth’; another left behind her wheelchair, started a family and referred to her symptoms as a ‘bad dream’.

Is this treatment too good to be true? The results of this trial were unveiled at a conference this week and the scientific community is now waiting to review and confirm the research data. As to the risk, a small number of patients died from infections that pounced after the initial chemotherapy weakened their immune system. Additionally, the treatment is not applicable for secondary-progressive MS patients, whose neural damage is too far advanced, but offers hope to many others.

Curated by Endre Szvetnik, Senior Editor at Sparrho.

Endre works with Sparrho Heroes to curate, translate and disseminate scientific research to the wider public.

(Psst, Endre distilled 13 research papers to save you 751.3 min)

Originally published at